According to a recent LinkedIn post from Monarch Medical Technologies, the company’s EndoTool insulin dosing platform is positioned as being implemented and supported primarily by clinicians rather than generic technology teams. The post notes that onboarding is guided by clinical experts from Glooko who have bedside experience, with training led by nurses who have used EndoTool in practice.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that hospitals adopting EndoTool receive dedicated clinical, technical, and project resources, alongside long-term support aligned with broader system goals. For investors, this emphasis on clinician-led implementation and tailored support may strengthen customer adoption and retention, potentially improving recurring revenue prospects and reinforcing Monarch’s positioning in the glycemic management and insulin dosing segment within hospital settings.